Viela's $75M series B to support BLA, autoimmune pipeline

After attracting multiple crossover investors to its latest venture round, Viela’s $75 million series B could be the last private round for the MedImmune spinout.

HBM Healthcare Investments led the financing with participation from fellow new investors Viking Global Investors, Cormorant Asset Management, Terra Magnum Capital Partners, Goldman Sachs, and Barer & Son Capital and existing investor Temasek. ...